Fri, December 19, 2008
Thu, December 18, 2008
Wed, December 17, 2008
Tue, December 16, 2008
Mon, December 15, 2008
Sun, December 14, 2008
Fri, December 12, 2008
Thu, December 11, 2008
Wed, December 10, 2008
Tue, December 9, 2008
Mon, December 8, 2008
Sun, December 7, 2008
Sat, December 6, 2008
Fri, December 5, 2008
Thu, December 4, 2008
Wed, December 3, 2008
[ Wed, Dec 03rd 2008 ] - Market Wire
Protherics PLC: Offer Update
Tue, December 2, 2008
Mon, December 1, 2008
Sun, November 30, 2008
Fri, November 28, 2008
Thu, November 27, 2008
Wed, November 26, 2008
Tue, November 25, 2008
[ Tue, Nov 25th 2008 ] - Market Wire
HST Global Quarterly Update

Reminder: Exelixis Announces December 12 Webcast of Its Fourth AnnualR&D Day


//health-fitness.news-articles.net/content/2008/ .. mber-12-webcast-of-its-fourth-annualr-d-day.html
Published in Health and Fitness on Monday, December 8th 2008 at 17:44 GMT by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (Nasdaq:EXEL) announced today that it will hold its Fourth Annual R&D Day on Friday, December 12, 2008 from 10:00 a.m. EST / 7:00 a.m. PST to 2:00 p.m. EST / 11:00 a.m. PST in New York. Exelixis management will discuss the company's corporate strategy, financial outlook and development pipeline.

The event will be webcast and may be accessed in the Event Calendar page under Investors at [ http://www.exelixis.com ].

An archive of this webcast will be available until 9:00 p.m. PST/12:00 a.m. EST on January 12, 2009. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is: 90996892.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at [ www.exelixis.com ].

Exelixis and the Exelixis logo are registered U.S. trademarks.


Publication Contributing Sources

Similar Health and Fitness Publications